This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Globus Medical (GMED) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Globus Medical (GMED) is optimistic about maintaining robust product portfolio along with strength in its domestic spine business.
Can Wall Street Sail Through December After a Record November?
by Nalak Das
At this stage, it will be prudent to invest in large-cap stocks with a favorable Zacks Rank and our VGM Score of A or B. These are GM, LB, LH, QRVO, PKI and HOLX.
Baxter (BAX) Announces Site Expansion to Improve Patient Care
by Zacks Equity Research
Baxter's (BAX) latest site expansion is aimed at better serving its client and patient pool along with employment creation.
Here's Why You Should Invest in Syneos Health (SYNH) Now
by Zacks Equity Research
Investors continue to be optimistic about Syneos Health (SYNH) on solid sequential recovery in the Clinical Solutions segment and strategic partnerships.
OPEC+ Meets: Global Week Ahead
by John Blank
Announcing an OPEC+ plan -- to add 2 million barrels of oil a day back on the global market -- poses a supply risk to this fragile oil price recovery. On the other hand, maintaining deep production cuts limits the income collected by OPEC+??members.
5 Best Momentum Picks Using Driehaus Strategy
by Nitish Marwah
After a detailed study of Driehaus' strategy, AAII concluded that it mainly focuses on strong earnings growth rates and impressive prospects to pick potential outperformers.
Here is Why Growth Investors Should Buy Hologic (HOLX) Now
by Zacks Equity Research
Hologic (HOLX) could produce exceptional returns because of its solid growth attributes.
Here's Why You Should Add ResMed (RMD) to Your Portfolio
by Zacks Equity Research
Investors continue to be positive about ResMed (RMD) owing to its potential in digital health and consistent high demand for its critical care products.
Hologic (HOLX) Gets Additional FDA Nod, to Aid HIV Testing
by Zacks Equity Research
Additional FDA approval for Hologic's (HOLX) molecular diagnostic test is expected to aid in the diagnosis of HIV infection.
Top Ranked Growth Stocks to Buy for November 25th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, November 25th
Medtronic's (MDT) Q2 Earnings Beat Estimates, Margins Fall
by Urmimala Biswas
Deferred procedures due to the pandemic impact Medtronic's (MDT) Q2 performance.
Why Hologic (HOLX) Could Be an Impressive Growth Stock
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Hologic (HOLX).
Hologic's (HOLX) Cervical Cancer Screening System Gets CE Mark
by Zacks Equity Research
Hologic (HOLX) becomes the provider of the first CE-Marked comprehensive cervical cancer screening portfolio with the new Genius Digital Diagnostics System.
Repro Med Systems (KRMD) Surges: Stock Moves 8.8% Higher
by Zacks Equity Research
Repro Med Systems (KRMD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
3 Best Buys from the Prospering Medical Instruments Industry
by Urmimala Biswas
Despite the challenges posed by the COVID-19 pandemic, higher demand for lab-testing products, digital influence, and AI and robotics is likely to lend support to the Zacks Medical - Instruments industry. TMO, IDXX and STE are well positioned to gain.
Top Ranked Growth Stocks to Buy for November 17th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, November 17th.
Top Stock Picks for Week of November 16, 2020
by Panel Of Zacks Experts
A Company to Watch in the Broader Technology Sector and One Making Big Inroads in Women's Health.
Here's Why You Should Add Hologic (HOLX) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Hologic (HOLX) on robust growth of the Diagnostics segment and regulatory approvals.
Amedisys (AMED) Banks on Home Health & Hospice Amid Cost Woe
by Zacks Equity Research
Amedisys (AMED) continues to benefit from the recent acquisitions of hospice care providers.
QIAGEN (QGEN) Launches COVID-19 Antigen Test With Ellume
by Zacks Equity Research
QIAGEN (QGEN) starts commercializing latest test after filing for FDA emergency use authorization (EUA) for symptomatic patients.
Hologic (HOLX) Updates Its Unifi Platform, Enhances Portfolio
by Zacks Equity Research
Hologic (HOLX) introduces upgrades to its Unifi Analytics platform to help mammography centers improve their workflow.
Hologic, Disney, Quidel, Alibaba, JD.com and Tencent highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Hologic, Disney, Quidel, Alibaba, JD.com and Tencent highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Hologic (HOLX)
by Kevin Cook
This leader in women's health diagnostics is ramping high double-digit growth on COVID testing
Top Ranked Growth Stocks to Buy for November 16th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, November 16th
Abbott (ABT) Launches Radiofrequency Ablation Device in U.S.
by Zacks Equity Research
Abbott (ABT) aims to expand its Neuromodulation portfolio with the latest launch of its radiofrequency ablation device.